Sunday, March 02, 2008 5:15:12 PM
The point, very simply, is that biotech have an OVERWHELMING history of making poor decisions about trial design - whether it is from false economy or shear ignorance of history (e.g. they never learn from their neighbors in the biotech world that changing entry criteria is far from benign no matter how well intentioned.)
If we want to claim that somehow RPRX management is different then they need to explain WHY they are smarter. Why they are different. What 5 calls have they made that were really good. Or prove that they have designed this trial correctly. But I would suggest that it is a mistake to assert that no designer/statistician would make such a mistake WHEN HISTORY SAYS THEY MAKE THEM ALL THE TIME. It seems to be small biotech culture.
What I find disturbing about this board is the amount of cool-aid as evidenced by the complete lack of curiousity about any of the details of trial design. In contrast, for Provenge there are a variety of longs at least asking what the interim is, what the Cox Regression coefficients are, ... . Where is that spirit here? I would suggest that it should worry you that there is no such curiousity here.
As to the lack of randomized p II trials in cancer research... I'd see that in the more cynical light of being more driven by the desire to get lucky by not asking too much of the phase II's
Well, my cynicism runs more along the lines of the edict never to assume malfeasance when incompetence is an adequate explanation - and I have seen plenty of outright incompetence in data interpretation and trial design. By companies with bigger names than the repros team.
The sorry thing here is that my first pass at the repros mgt team gives them higher than normal marks - but I may not get to a second pass because I cannot get better data with which to calibrate them.
C
Recent RPRX News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 09:12:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2026 10:02:29 PM
- Royalty Pharma Announces Expansion of Leadership Team • GlobeNewswire Inc. • 03/17/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:11:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 09:52:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:26:17 PM
- Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:10:00 AM
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:01:00 AM
- Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:08:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 10:06:45 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/20/2026 09:27:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:03:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:02:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:02:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 02:04:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 12:37:12 PM
- Royalty Pharma Reports Q4 and Full Year 2025 Results • GlobeNewswire Inc. • 02/11/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 10:07:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/03/2026 10:31:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2026 10:28:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 09:10:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:48:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 10:00:25 PM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
